Inve India ▾

Sai Life share price & results

Sai Life· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Integrated CRDMO serving global pharma/biotech from drug discovery through commercial manufacturing.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue554 ₹ crore+11.7% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin27.0 %+3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit73.0 ₹ crore+21.7% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity15.91 %+4.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-3.79 %−0.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)17.63 %+13.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 4 judged targets kept · 9 open · verdicts reflect calls analysed to Q1 FY27.

Sai Life management guidance track record on Inve: 13 targets tracked across analysed earnings calls (1 achieved, 3 missed, 9 open).

TargetOriginal wordingSaidLatest callVerdict
EBITDA Margin28-30% steady state in the next 2-3 years
Call transcript, Q3 FY25 · 7 Feb 2025		Q3 FY25Q1 FY27:Management reiterated confidence in sustaining the 28-30% EBITDA range.
Call transcript, Q1 FY27 · 7 Aug 2026		Achieved
Total Capex FY26Close to INR 700 crores for FY26
Call transcript, Q4 FY25 · 14 May 2025		Q4 FY25Q1 FY27:FY26 has concluded, but management did not provide a final figure for the full-year capex spend. Focus shifted to FY27 guidance.
Call transcript, Q1 FY27 · 7 Aug 2026		Ghosted
Manufacturing Capacity Addition100 KL in Q1 FY26
Call transcript, Q3 FY25 · 7 Feb 2025		Q3 FY25Q1 FY27:Promise relates to a past quarter, status remains unchanged.
Call transcript, Q1 FY27 · 7 Aug 2026		Diluted

Source: Inve Guidance Tracker for Sai Life · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Sai Life's 13 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 10 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,445.3 +3.58% · +₹50

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +61.5% 1Y

₹0.8k₹1.0k₹1.2k₹1.4k₹1.6kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 7 Nov 2025Q3 FY26 — 6 Feb 2026Q1 FY27 — 7 Aug 2026

1Y: ₹895.05 on 24 Oct 2025 → ₹1,445.3. High ₹1,675.4 (9 Sept 2026), low ₹795 (23 Jan 2026).

Previous close
₹1,395.3
Market cap
₹30.7k Cr
52-week range
₹795 – ₹1,675.4
One year
+64.58%
Price to earnings (TTM to Jun 2026)
83.68×
Return on equity (TTM to Jun 2026)
15.91%

Overview

Symbol
NSE:SAILIFE
Exchange
NSE
Currency
INR

What Sai Life does

Based on the company's own presentations, annual report and earnings calls.

Sai Life Sciences is a fully integrated Contract Research, Development and Manufacturing Organisation (CRDMO) focused on small-molecule new chemical entities, partnering with global pharmaceutical and biotech companies from early discovery through commercial-scale manufacturing. It operates two reported business lines: Discovery Services (CRO), covering medicinal and synthetic chemistry, biology, DMPK and toxicology; and CMC/Manufacturing Services (CDMO), covering process R&D, analytical development and GMP-compliant manufacturing including complex and HPAPI chemistry. Discovery and process R&D are carried out at an integrated R&D campus in Hyderabad and satellite labs in Manchester (UK) and Greater Boston (US), while commercial-scale manufacturing is based at facilities in Hyderabad and Bidar, India. It earns revenue through outsourced discovery, development and manufacturing contracts with pharmaceutical innovators, including many of the world's largest pharma companies.

Segments

  • CDMO
  • CRO
Installed manufacturing capacity
700 KL
Production trains
80
Global R&D and manufacturing locations
4 (Hyderabad & Bidar, India; Manchester, UK; Greater Boston, US)
Total employees
3,800+
Active global clients
300+, including 19 of the top 25 global pharma companies
Active commercial (NCE) molecules
34
Founded 1999Headquarters Hyderabad, Telangana, IndiaEmployees 3,800 (FY26) Company website

How the price took the results

close before → close after

Q1 FY27
−3.4%
7 Aug
Q3 FY26
+4.8%
6 Feb
Q2 FY26
−5.1%
7 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sai Life

Free account: one company. Everything above stays public.

Write why you follow Sai Life and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sai Life

Guides on how to read this kind of business and the numbers that matter.